USFDA cautions Aurobindo Pharma's oral solids formulation facility of regulatory action

According to USFDA's definitions, OAI means "objectionable conditions were found and regulatory administrative sanctions by FDA are indicated" during inspections. The company said that it believes that this OAI classification will not have any material impact on the existing revenues or the supplies to its US business at this juncture.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2UjbeUj
via IFTTT